Literature DB >> 20829343

Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma.

Khaleque Newaz Khan1, Michio Kitajima, Koichi Hiraki, Akira Fujishita, Masahiro Nakashima, Tadayuki Ishimaru, Hideaki Masuzaki.   

Abstract

BACKGROUND: We recently demonstrated the effect of gonadotrophin-releasing hormone agonist (GnRHa) on tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma. Here, we investigated expression of GnRH receptors (GnRHRs) and effect of GnRHa on the proliferation of cells derived from endometria and pathological lesions of women with these reproductive diseases.
METHODS: Biopsy specimens were collected from lesions and corresponding endometria of 35 women with pelvic endometriosis, 45 women with ovarian endometrioma, 35 women with adenomyosis and 56 women with uterine myoma during laparoscopy or laparotomy. The gene and protein expressions of GnRHR in eutopic/ectopic cells and tissues were examined by reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry. The immunoreactivity of GnRHR in tissue was analysed by quantitative-histogram (Q-H) scores. The exogenous effect of GnRHa on cell proliferation was examined by 5-bromo-2-deoxyuridine incorporation assay. The Ki-67-immunoreactive cell proliferation index was analysed in biopsy specimens derived from GnRHa-treated and -non-treated women.
RESULTS: Types I and II GnRHRs mRNA and proteins were expressed in eutopic endometria and pathological lesions derived from women with endometriosis, adenomyosis and uterine myoma. GnRHR expression was the highest in the menstrual phase when compared with other phases of the menstrual cycle. Higher Q-H scores of GnRHR immunoreaction were found in blood-filled opaque red lesions than in other peritoneal lesions. Exogenous treatment with GnRHa significantly suppressed the proliferation of cells derived from respective endometria and pathological lesions when compared with GnRHa-non-treated cells.
CONCLUSIONS: Local tissue expression of GnRHR was detected in endometriosis, adenomyosis and uterine myoma. In addition to a hypo-estrogenic effect, a direct anti-proliferative effect of GnRHa may be involved in the regression of these reproductive diseases with consequent remission of clinical symptoms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20829343     DOI: 10.1093/humrep/deq240

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  21 in total

1.  Global Transcriptome Abnormalities of the Eutopic Endometrium From Women With Adenomyosis.

Authors:  Christopher N Herndon; Lusine Aghajanova; Shaina Balayan; David Erikson; Fatima Barragan; Gabriel Goldfien; Kim Chi Vo; Shannon Hawkins; Linda C Giudice
Journal:  Reprod Sci       Date:  2016-05-27       Impact factor: 3.060

2.  Artificial Cycle with or without a Depot Gonadotropin-releasing Hormone Agonist for Frozen-thawed Embryo Transfer: An Assessment of Infertility Type that Is Most Suitable.

Authors:  Di Xie; Fan Chen; Shou-Zhen Xie; Zhi-Lan Chen; Ping Tuo; Rong Zhou; Juan Zhang
Journal:  Curr Med Sci       Date:  2018-08-20

Review 3.  Evidence-Based Management of Uterine Fibroids With Botanical Drugs-A Review.

Authors:  Masita Arip; Vi Lien Yap; Mogana Rajagopal; Malarvili Selvaraja; K Dharmendra; Sasikala Chinnapan
Journal:  Front Pharmacol       Date:  2022-06-22       Impact factor: 5.988

4.  In vitro apoptosis effects of GnRHII on endometrial stromal cells from patients with endometriosis.

Authors:  Fengying Huang; Ying Zou; Huanping Wang; Jing Cao; Tuanfang Yin
Journal:  Int J Clin Exp Pathol       Date:  2013-07-15

5.  [Effect of GnRHa therapy following conservative laparoscopic surgery for endometriosis on clinical pregnant rate in patients with endometriosis-associated infertility].

Authors:  Li-Qing He; Xu-Zi Cai; Yan Wang; Xue-Feng Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-05-20

6.  Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.

Authors:  Ayman Al-Hendy; Andrea S Lukes; Alfred N Poindexter; Roberta Venturella; Claudio Villarroel; Hilary O D Critchley; Yulan Li; Laura McKain; Juan C Arjona Ferreira; Andria G M Langenberg; Rachel B Wagman; Elizabeth A Stewart
Journal:  N Engl J Med       Date:  2021-02-18       Impact factor: 91.245

7.  GnRH agonists induce endometrial epithelial cell apoptosis via GRP78 down-regulation.

Authors:  Huinan Weng; Fenghua Liu; Shuiwang Hu; Li Li; Yifeng Wang
Journal:  J Transl Med       Date:  2014-11-04       Impact factor: 5.531

8.  Efficacy and safety of remifemin on peri-menopausal symptoms induced by post-operative GnRH-a therapy for endometriosis: a randomized study versus tibolone.

Authors:  Jiming Chen; Hongyan Gao; Qin Li; Jing Cong; Jie Wu; Dahua Pu; Guohua Jiang
Journal:  Med Sci Monit       Date:  2014-10-16

9.  Efficacy and safety investigation of Kuntai capsule for the add-back therapy of gonadotropin releasing hormone agonist administration to endometriosis patients: a randomized, double-blind, blank- and tibolone-controlled study.

Authors:  Ji-Ming Chen; Hong-Yan Gao; Yi Ding; Xia Yuan; Qing Wang; Qin Li; Guo-Hua Jiang
Journal:  Chin Med J (Engl)       Date:  2015-02-20       Impact factor: 2.628

10.  Ultra-Long GnRH Agonist Protocol During IVF/ICSI Improves Pregnancy Outcomes in Women With Adenomyosis: A Retrospective Cohort Study.

Authors:  Jie Lan; Yaoqiu Wu; Zexuan Wu; Yingchen Wu; Rong Yang; Ying Liu; Haiyan Lin; Xuedan Jiao; Qingxue Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-31       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.